{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:32:04Z","timestamp":1786537924194,"version":"build-2736575974"},"reference-count":85,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathophysiology"],"abstract":"<jats:p>Erythropoiesis-targeted doping remains a major challenge for sports medicine because pharmacological and genetic manipulation of erythropoiesis can improve oxygen transport and endurance performance while increasing the risk of serious cardiovascular complications. Erythropoiesis-targeting strategies extend beyond recombinant erythropoietin (EPO) to include hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), modified erythropoietin receptor (EPOR) agonists, transforming growth factor beta (TGF-\u03b2) signaling inhibitors, cytoprotective EPO derivatives, and gene- or cell-based approaches, and require complementary detection strategies based on direct analytical methods and the Athlete Biological Passport (ABP). Although they may enhance oxygen delivery and endurance performance, excessive stimulation of erythropoiesis may increase blood viscosity, impair vascular function, and elevate the risk of hypertension, thromboembolic complications, and other cardiovascular (CV) events. Erythropoiesis-targeted doping has evolved beyond recombinant EPO into a diverse group of pharmacological and genetic strategies that require increasingly sophisticated detection approaches. A thorough understanding of their molecular mechanisms and cardiovascular consequences is essential for improving anti-doping surveillance and protecting athlete health. This review summarizes current erythropoiesis-targeting agents, their mechanisms of action, detection strategies, cardiovascular risks, and implications for anti-doping practice.<\/jats:p>","DOI":"10.3390\/pathophysiology33030062","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:02:11Z","timestamp":1786532531000},"page":"62","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erythropoiesis-Targeted Doping in Sports: From Improved Oxygen Transport to Cardiovascular Risk"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2166-7849","authenticated-orcid":false,"given":"Gabriela","family":"Chlebowska","sequence":"first","affiliation":[{"name":"Students\u2019 Scientific Society, Department of Pharmacology, Faculty of Medicine, University of Opole, 45-052 Opole, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9157-6298","authenticated-orcid":false,"given":"Krzysztof","family":"Michalak","sequence":"additional","affiliation":[{"name":"Institute of Medical Sciences, Faculty of Medicine, University of Opole, 45-052 Opole, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8680-6740","authenticated-orcid":false,"given":"\u0141ukasz","family":"Mazur","sequence":"additional","affiliation":[{"name":"Institute of Chemistry, University of Opole, 45-052 Opole, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9736-422X","authenticated-orcid":false,"given":"Wioletta","family":"Szczurek-Wasilewicz","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Opole, 45-052 Opole, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin","volume":"316","author":"Eschbach","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1249\/MSS.0000000000001777","article-title":"Effects of EPO on Blood Parameters and Running Performance in Kenyan Athletes","volume":"51","author":"Haile","year":"2019","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00421-015-3322-6","article-title":"RhEPO Improves Time to Exhaustion by Non-Hematopoietic Factors in Humans","volume":"116","author":"Annaheim","year":"2016","journal-title":"Eur. J. Appl. Physiol."},{"key":"ref_4","unstructured":"World Anti-Doping Agency (2025). The 2026 Prohibited List: International Standard, World Anti-Doping Agency."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2017.01.033","article-title":"Erythropoietin as a Performance-Enhancing Drug: Its Mechanistic Basis, Detection, and Potential Adverse Effects","volume":"464","author":"Salamin","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/dta.3666","article-title":"Homologous Blood Transfusion and Doping: Where Are We Now?","volume":"16","author":"Marchand","year":"2024","journal-title":"Drug Test. Anal."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"eadv7234","DOI":"10.1126\/sciadv.adv7234","article-title":"High-Throughput Multiplexed Gene and Cell Doping Analysis through CRISPR-Cas12a System Integrated with Blood Direct PCR","volume":"11","author":"Yi","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"124455","DOI":"10.1016\/j.talanta.2023.124455","article-title":"CRISPR\/deadCas9-Based High-Throughput Gene Doping Analysis (HiGDA): A Proof of Concept for Exogenous Human Erythropoietin Gene Doping Detection","volume":"258","author":"Yi","year":"2023","journal-title":"Talanta"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Naumann, N., Pa\u00dfreiter, A., Thomas, A., Krug, O., Walpurgis, K., and Thevis, M. (2023). Analysis of Potential Gene Doping Preparations for Transgenic DNA in the Context of Sports Drug Testing Programs. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115835"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s00421-020-04419-0","article-title":"Additive Effect of Erythropoietin Use on Exercise-Induced Endothelial Activation and Hypercoagulability in Athletes","volume":"120","author":"Heuberger","year":"2020","journal-title":"Eur. J. Appl. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0301-472X(03)00006-7","article-title":"Darbepoetin Alfa Has a Longer Circulating Half-Life and Greater in Vivo Potency than Recombinant Human Erythropoietin","volume":"31","author":"Egrie","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1249\/mss.0b013e31811e9d55","article-title":"Detection of Darbepoetin Alfa Misuse in Urine and Blood: A Preliminary Investigation","volume":"39","author":"Morkeberg","year":"2007","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3324\/haematol.2009.006809","article-title":"Detection of Continuous Erythropoietin Receptor Activator in Blood and Urine in Anti-Doping Control","volume":"94","author":"Lasne","year":"2009","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/dta.1381","article-title":"Detection of EPO-Fc Fusion Protein in Human Blood: Screening and Confirmation Protocols for Sports Drug Testing","volume":"4","author":"Reichel","year":"2012","journal-title":"Drug Test. Anal."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1182\/blood-2008-08-172320","article-title":"CNTO 530 Functions as a Potent EPO Mimetic via Unique Sustained Effects on Bone Marrow Proerythroblast Pools","volume":"113","author":"Sathyanarayana","year":"2009","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12967-025-06632-x","article-title":"Correction: Overview of Preclinical and Phase II Clinical Studies on Pegmolesatide\u2019s Long-Term Erythropoiesis Stimulating Effect via EPOR-Mediated Signal Transduction","volume":"23","author":"Ma","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"JASN"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Creang\u0103, E.-C., Ott, C., Nicolae, A.-C., Dr\u0103goi, C.M., and Stan, R. (2025). Roxadustat as a Hypoxia-Mimetic Agent: Erythropoietic Mechanisms, Bioanalytical Detection, and Regulatory Considerations in Sports Medicine. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47090734"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/ndt\/gfab349","article-title":"Erratum to: Roxadustat for the Treatment of Anaemia in Chronic Kidney Disease Patients Not on Dialysis: A Phase 3, Randomised, Open-Label, Active-Controlled Study (DOLOMITES)","volume":"37","author":"Barratt","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/dta.3771","article-title":"Simultaneous Detection of Three Hypoxia-Inducible Factor Stabilizers\u2014Molidustat, Roxadustat, and Vadadustat\u2014In Multiple Keratinized Matrices and Its Application in a Doping Context","volume":"17","author":"Checkouri","year":"2025","journal-title":"Drug Test. Anal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/jat\/bkad057","article-title":"Segmental Analysis and Long-Term Monitoring of Vadadustat in Equine Hair for the Purpose of Doping Control","volume":"47","author":"Ishii","year":"2023","journal-title":"J. Anal. Toxicol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0014-4827(02)00013-7","article-title":"Regulation of Human Erythropoiesis by Activin A, BMP2, and BMP4, Members of the TGF\u03b2 Family","volume":"282","author":"Bartholin","year":"2003","journal-title":"Exp. Cell Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.12838","article-title":"An Activin Receptor II A Ligand Trap Promotes Erythropoiesis Resulting in a Rapid Induction of Red Blood Cells and Haemoglobin","volume":"165","author":"Carrancio","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/dta.2093","article-title":"Testing for the Erythropoiesis-stimulating Agent Sotatercept\/ACE-011 (ActRIIA-Fc) in Serum by Means of Western Blotting and LC-HRMS","volume":"8","author":"Walpurgis","year":"2016","journal-title":"Drug Test. Anal."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hatzimichael, E., Timotheatou, D., Koumpis, E., Benetatos, L., and Makis, A. (2022). Luspatercept: A New Tool for the Treatment of Anemia Related to \u03b2-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis. Diseases, 10.","DOI":"10.3390\/diseases10040085"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41419-020-2276-8","article-title":"Erythropoietin and its Derivatives: From Tissue Protection to Immune Regulation","volume":"11","author":"Peng","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0406491101","article-title":"Erythropoietin Mediates Tissue Protection Through an Erythropoietin and Common \u03b2-Subunit Heteroreceptor","volume":"101","author":"Brines","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/dta.2956","article-title":"The Analytical Approach for Detection of Carbamylated Erythropoietin for Doping Control Purposes","volume":"12","author":"Kaliszewski","year":"2020","journal-title":"Drug Test. Anal."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/dta.3664","article-title":"Gene Doping Detection in the Era of Genomics","volume":"16","author":"Li","year":"2024","journal-title":"Drug Test. Anal."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sugasawa, T., Nakano, T., Fujita, S., Matsumoto, Y., Ishihara, G., Aoki, K., Yanazawa, K., Ono, S., Tamai, S., and Manevich, L. (2021). Proof of Gene Doping in a Mouse Model with a Human Erythropoietin Gene Transferred Using an Adenoviral Vector. Genes, 12.","DOI":"10.20944\/preprints202107.0034.v1"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sugasawa, T., Hirokawa, A., Otani, N., Kanki, Y., Nguyen, K.D., Takemasa, T., Watanabe, K., Takeuchi, Y., Yahagi, N., and Takahashi, Y. (2024). Detection Method for Gene Doping in a Mouse Model Expressing Human Erythropoietin from Adeno-Associated Virus Vector-9. Genes, 15.","DOI":"10.20944\/preprints202405.0167.v1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5114\/reum\/224664","article-title":"The Role and Potential of CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Systemic Sclerosis","volume":"64","author":"Michalak","year":"2026","journal-title":"Reumatologia"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bakirova, S., Baigenzhin, A., Tuganbekova, S., Askarov, M., Chuvakova, E., Doskali, M., and Doszhan, A. (2025). Comparative Efficacy of Autologous Hematopoietic and Mesenchymal Stem Cell Transplantation in Patients with Systemic Sclerosis: A Systematic Review. J. Clin. Med., 15.","DOI":"10.3390\/jcm15010261"},{"key":"ref_35","unstructured":"World Anti-Doping Agency (2024). Harmonization of Analysis and Reporting of Erythropoietin (EPO)-Receptor Agonists (ERAs) and Transforming Growth Factor-Beta (TGF-\u03b2) Signalling Inhibitors by Polyacrylamide Gel Electrophoretic (PAGE) Analytical Methods, World Anti-Doping Agency. Available online: https:\/\/www.wada-ama.org\/sites\/default\/files\/2024-03\/td2024epo_eng_final.pdf."},{"key":"ref_36","unstructured":"U.S. Food and Drug Administration (2026, July 27). MIRCERA\u00ae (Methoxy Polyethylene Glycol-Epoetin Beta) Injection, for Intravenous or Subcutaneous Use: Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/Drugsatfda_docs\/Label\/2023\/125164s087lblcorretion.Pdf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-Inducible Factor\u2013Prolyl Hydroxylase Inhibitors in the Treatment of Anemia of Chronic Kidney Disease","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int. Suppl."},{"key":"ref_38","unstructured":"U.S. National Library of Medicine (2026, July 27). WINREVAIR\u2122 (Sotatercept-csrk) for Injection, for Subcutaneous Use: Full Prescribing Information, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=21693ee2-cd23-4137-ac67-066bb3a4a9b7&type=display."},{"key":"ref_39","unstructured":"U.S. National Library of Medicine (2026, July 27). REBLOZYL\u00ae (Luspatercept-aamt) for Injection, for Subcutaneous Use: Full Prescribing Information, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=82f4d266-3f52-41eb-86ba-0abf3cf468e8&type=display."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood-2006-01-0028","article-title":"False-Positive Detection of Recombinant Human Erythropoietin in Urine Following Strenuous Physical Exercise","volume":"107","author":"Beullens","year":"2006","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1016\/j.chroma.2010.09.034","article-title":"Rapid Affinity Purification of Erythropoietin from Biological Samples Using Disposable Monoliths","volume":"1217","author":"Dehnes","year":"2010","journal-title":"J. Chromatogr. A"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ab.2011.09.021","article-title":"Rapid Detection of Erythropoiesis-Stimulating Agents in Urine and Serum","volume":"420","author":"Drevin","year":"2012","journal-title":"Anal. Biochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/rcm.5109","article-title":"Synthesis, Characterisation, and Mass Spectrometric Detection of a Pegylated EPO-mimetic Peptide for Sports Drug Testing Purposes","volume":"25","author":"Thomas","year":"2011","journal-title":"Rapid. Comm. Mass. Spectrom."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/dta.406","article-title":"Detection of EPO Doping and Blood Doping: The Haematological Module of the Athlete Biological Passport","volume":"4","author":"Schumacher","year":"2012","journal-title":"Drug Test. Anal."},{"key":"ref_45","first-page":"1053","article-title":"Effect of Altitude on Second-Generation Blood Tests to Detect Erythropoietin Abuse by Athletes","volume":"88","author":"Ashenden","year":"2003","journal-title":"Haematologica"},{"key":"ref_46","first-page":"1413","article-title":"Current Limitations of the Athlete\u2019s Biological Passport Use in Sports","volume":"49","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_47","first-page":"24","article-title":"Athlete Biological Passport: Longitudinal Biomarkers and Statistics in the Fight against Doping","volume":"75","year":"2024","journal-title":"Arch. Ind. Hyg. Toxicol."},{"key":"ref_48","unstructured":"World Anti-Doping Agency (2025). 2024 Anti-Doping Testing Figures Report, World Anti-Doping Agency. Available online: https:\/\/www.wada-ama.org\/sites\/default\/files\/2025-12\/2024_Anti-Doping%20Testing%20Figures%20Report_FINAL_v3.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40279-017-0765-4","article-title":"Doping in Two Elite Athletics Competitions Assessed by Randomized-Response Surveys","volume":"48","author":"Ulrich","year":"2018","journal-title":"Sports Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Faiss, R., Saugy, J., Zollinger, A., Robinson, N., Schuetz, F., Saugy, M., and Garnier, P.-Y. (2020). Prevalence Estimate of Blood Doping in Elite Track and Field Athletes During Two Major International Events. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.00160"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1373\/clinchem.2010.156067","article-title":"Prevalence of Blood Doping in Samples Collected from Elite Track and Field Athletes","volume":"57","author":"Sottas","year":"2011","journal-title":"Clin. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40279-014-0247-x","article-title":"Prevalence of Doping Use in Elite Sports: A Review of Numbers and Methods","volume":"45","author":"Kuipers","year":"2015","journal-title":"Sports Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40798-024-00721-9","article-title":"Doping Prevalence among U.S. Elite Athletes Subject to Drug Testing under the World Anti-Doping Code","volume":"10","author":"Davoren","year":"2024","journal-title":"Sports Med.-Open"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dietz, P., Ulrich, R., Dalaker, R., Striegel, H., Franke, A.G., Lieb, K., and Simon, P. (2013). Associations between Physical and Cognitive Doping\u2013A Cross-Sectional Study in 2.997 Triathletes. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078702"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of Erythropoiesis by Hypoxia-Inducible Factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-042921-102602","article-title":"Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations","volume":"74","author":"Semenza","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"T\u00f3thov\u00e1, Z., Tomc, J., Debeljak, N., and Sol\u00e1r, P. (2021). STAT5 as a Key Protein of Erythropoietin Signalization. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137109"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2310\/JIM.0b013e31820fb28c","article-title":"The Erythropoietin Receptor: Molecular Structure and Hematopoietic Signaling Pathways","volume":"59","author":"Watowich","year":"2011","journal-title":"J. Investig. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"T\u00f3thov\u00e1, Z., \u0160emel\u00e1kov\u00e1, M., Sol\u00e1rov\u00e1, Z., Tomc, J., Debeljak, N., and Sol\u00e1r, P. (2021). The Role of PI3K\/AKT and MAPK Signaling Pathways in Erythropoietin Signalization. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147682"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s40265-022-01783-3","article-title":"Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors","volume":"82","author":"Locatelli","year":"2022","journal-title":"Drugs"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ogawa, C., Tsuchiya, K., and Maeda, K. (2023). Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24033037"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Bartnicki, P. (2024). Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081884"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1249\/MSS.0000000000003052","article-title":"Microdoses of Recombinant Human Erythropoietin Enhance Time Trial Performance in Trained Males and Females","volume":"55","author":"Graae","year":"2023","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e14243","DOI":"10.1111\/sms.14243","article-title":"Contemporary Blood Doping\u2014Performance, Mechanism, and Detection","volume":"34","author":"Nordsborg","year":"2024","journal-title":"Scand. Med. Sci. Sports"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Durussel, J., Daskalaki, E., Anderson, M., Chatterji, T., Wondimu, D.H., Padmanabhan, N., Patel, R.K., McClure, J.D., and Pitsiladis, Y.P. (2013). Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056151"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e000716","DOI":"10.1136\/bmjsem-2019-000716","article-title":"Effect of Erythropoietin on Athletic Performance: A Systematic Review and Meta-Analysis","volume":"6","author":"Trinh","year":"2020","journal-title":"BMJ Open Sport Exerc. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/bcp.12034","article-title":"Erythropoietin Doping in Cycling: Lack of Evidence for Efficacy and a Negative Risk\u2013Benefit","volume":"75","author":"Heuberger","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1113\/jphysiol.2006.122689","article-title":"Erythropoietin Treatment Elevates Haemoglobin Concentration by Increasing Red Cell Volume and Depressing Plasma Volume","volume":"578","author":"Lundby","year":"2007","journal-title":"J. Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1113\/jphysiol.2010.194241","article-title":"Erythropoietin Down-regulates Proximal Renal Tubular Reabsorption and Causes A Fall in Glomerular Filtration Rate in Humans","volume":"589","author":"Olsen","year":"2011","journal-title":"J. Physiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1113\/jphysiol.2010.195917","article-title":"Effects of Recombinant Human Erythropoietin in Normal Humans","volume":"589","author":"Lundby","year":"2011","journal-title":"J. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1210\/er.2013-1058","article-title":"Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement","volume":"35","author":"Pope","year":"2014","journal-title":"Endocr. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/ndt\/gfx324","article-title":"Mechanisms and Mediators of Hypertension Induced by Erythropoietin and Related Molecules","volume":"33","author":"Agarwal","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_74","first-page":"278","article-title":"Acute Coronary Syndrome with Intraventricular Thrombus after Using Erythropoietin","volume":"13","author":"Kurtul","year":"2013","journal-title":"Anadolu Kardiyol. Derg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.58.4.665","article-title":"Cyclist\u2019s Doping Associated with Cerebral Sinus Thrombosis","volume":"58","author":"Lage","year":"2002","journal-title":"Neurology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1152\/japplphysiol.90484.2008","article-title":"Does Recombinant Human Epo Increase Exercise Capacity by Means Other than Augmenting Oxygen Transport?","volume":"105","author":"Lundby","year":"2008","journal-title":"J. Appl. Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/FTD.0b013e31820032c4","article-title":"Applications and Biomonitoring Issues of Recombinant Erythropoietins for Doping Control","volume":"33","author":"Tsitsimpikou","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1681\/ASN.2004110959","article-title":"Epoetin-Induced Autoimmune Pure Red Cell Aplasia","volume":"16","author":"Casadevall","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1212\/WNL.49.3.686","article-title":"Erythropoietin-associated hypertensive posterior leukoencephalopathy","volume":"49","author":"Delanty","year":"1997","journal-title":"Neurology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13105-014-0374-8","article-title":"Erythropoietin Enhances Whole Body Lipid Oxidation during Prolonged Exercise in Humans","volume":"71","author":"Caillaud","year":"2015","journal-title":"J. Physiol. Biochem."},{"key":"ref_81","first-page":"161","article-title":"Recombinant Human Erythropoietin Pretreatment Attenuates Myocardial Infarct size: A Possible Mechanism Involves Heat Shock Protein 70 and Attenuation of Nuclear Factor-kappaB","volume":"35","author":"Xu","year":"2005","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2040-7378-1-4","article-title":"Erythropoietin: A Multimodal Neuroprotective Agent","volume":"1","author":"Byts","year":"2009","journal-title":"Exp. Transl. Stroke Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2003-01-0223","article-title":"Erythropoietin Is a Potent Physiologic Stimulus for Endothelial Progenitor Cell Mobilization","volume":"102","author":"Heeschen","year":"2003","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jacc.2005.03.044","article-title":"Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction","volume":"46","author":"Lipsic","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Steppich, B., Groha, P., Ibrahim, T., Schunkert, H., Laugwitz, K.-L., Hadamitzky, M., Kastrati, A., and Ott, I. (2017). Effect of Erythropoietin in Patients with Acute Myocardial Infarction: Five-Year Results of the REVIVAL-3 Trial. BMC Cardiovasc. Disord., 17.","DOI":"10.1186\/s12872-016-0464-3"}],"container-title":["Pathophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1873-149X\/33\/3\/62\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:46:06Z","timestamp":1786535166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1873-149X\/33\/3\/62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pathophysiology33030062"],"URL":"https:\/\/doi.org\/10.3390\/pathophysiology33030062","relation":{},"ISSN":["1873-149X"],"issn-type":[{"value":"1873-149X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}